17 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Molecular Tools for Nucleic Acid Manipulation for Biological Intervention (MMBio)
Date du début: 1 janv. 2017, Date de fin: 31 déc. 2020,
MMbio will bridge the classically separate disciplines of Chemistry and Biology by assembling leading experts from academia and non-academic partners (industry, technology transfer & science communication) to bring about systems designed to interfere therapeutically with gene expression in living cells. Expertise in nucleic acid synthesis, its molecular recognition and chemical reactivity is combi ...
Voir le projet
13
Participants partenaires
TERMINÉ
Connecting Patients and Carers using wearable sensor technology (NIGHTINGALE)
Date du début: 1 nov. 2016, Date de fin: 31 oct. 2020,
Safest, reliable, individualised care of patients at-risk of deterioration needs patients themselves to play an active role in their care whenever possible: late detection or escalation of deterioration causes avoidable harms, and deaths. In this project we will challenge industry to develop robust monitoring and communications systems that connect patients, carers and health professionals, provid ...
Voir le projet
5
Participants partenaires
TERMINÉ
Clinical study in Parkinson's disease with two unique goals: 1) Proof-of-concept of CDNF protein for disease modification; 2) Validation of clinically tested device for intracerebral drug delivery (TreatER)
Date du début: 1 janv. 2017, Date de fin: 31 déc. 2019,
The main focus of TreatER is conducting a randomized, placebo-controlled, first-in-human, proof-of-concept, safety and efficacy study of intracerebrally administered CDNF protein therapy in patients with Parkinson’s disease (PD), using a neurosurgically implanted Drug Delivery System (DDS), which will also be clinically validated in the study. Thus the TreatER project has two independent goals, ei ...
Voir le projet
12
Participants partenaires
TERMINÉ
Lifestyle intervention in the perioperative process through digital service (LIVE INCITE)
Date du début: 1 nov. 2016, Date de fin: 30 juin 2019,
Lifestyle factors of the patient (e.g. smoking, hazardous alcohol drinking and malnutrition) are proven to be independent risk factors negatively impacting health outcome in the perioperative process. Evidence suggests that the implementation of intensive lifestyle intervention programs can significantly reduce the post-surgery complication risk and rehabilitation time . However, implementation of ...
Voir le projet
4
Participants partenaires
TERMINÉ
Regenerative treatment of complete Traumatic Spinal Cord injury with a surgical implantation of a biodegradable device with FGF1 and nerve grafts (SC0806)
Date du début: 1 janv. 2015, Date de fin: 31 déc. 2018,
Today there is no regenerative therapy available for treatment of complete spinal cord injuries (SCI). BioArctic Neuroscience develops a novel treatment of complete SCI. The method is based on the regeneration of functional nerves in the injured spinal cord. Nerve grafts are transplanted into the injured spinal cord, by using a biodegradable device, loaded with a growth factor and nerve grafts (th ...
Voir le projet
6
Participants partenaires
TERMINÉ
Development of a prophylactic treatment for the prevention of fetal/neonatal alloimmune thrombocytopenia (FNAIT) (PROFNAIT)
Date du début: 1 août 2012, Date de fin: 31 juil. 2018,
Objective--The project aims to develop an anti HPA-1a immunoglobulin (IgG), Tromplate® that can prevent post delivery immunisation of the mother against the Human Platelet Antigen-1a (HPA-1a). This prophylactic treatment will prevent Fetal/Neonatal Alloimmune Thrombocytopenia (FNAIT) in the fetus/newborn in subsequent pregnancies.FNAIT--FNAIT is a rare but potentially serious condition which affec ...
Voir le projet
13
Participants partenaires
TERMINÉ
Improving Outcome of Necrotizing Fasciitis: Elucidation of Complex Host and Pathogen Signatures that Dictate Severity of Tissue Infection (INFECT)
Date du début: 1 janv. 2013, Date de fin: 31 déc. 2017,
The overall goal with INFECT is to advance our understanding of the pathophysiological mechanisms, prognosis, and diagnosis of the multifactorial highly lethal NSTIs. The fulminant course of NSTIs (in the order of hours) demands immediate diagnosis and adequate interventions in order to salvage lives and limbs. However, diagnosis and management are difficult due to heterogeneity in clinical presen ...
Voir le projet
16
Participants partenaires
TERMINÉ
Adoptive engineered T cell Trials to Achieve Cancer Killing (ATTACK)
Date du début: 1 déc. 2012, Date de fin: 30 nov. 2017,
The aim of this research is to exploit technology for nucleic acid delivery through the clinical testing of adoptive engineered T cells to treat cancer. Recent innovative developments in cancer gene-immunotherapy have led to very encouraging early clinical results. However, the use of engineered T cells is a challenging and complex field with further development and more proof-of-principle trials ...
Voir le projet
16
Participants partenaires
TERMINÉ
Adaptive and innovative Radiation Treatment FOR improving Cancer patients treatment outcomE (ARTFORCE)
Date du début: 1 avr. 2011, Date de fin: 30 sept. 2017,
Loco-regional treatment is the mainstay of cancer cures in non small lung and head and neck cancer. For advanced stage cancer, dose intense multimodality treatment is required yet affected by substantial side effects. Our aim is to improve treatment outcome in locally advanced head and neck and lung cancer patients by:1. Optimizing local control by introducing novel radiation techniques resulting ...
Voir le projet
14
Participants partenaires
TERMINÉ
Zero Emission bUs Systems (ZEEUS)
Date du début: 1 nov. 2013, Date de fin: 30 avr. 2017,
Electrification of the public transport is a raising trend in Europe, and electric buses are soon expected to enter markets as one of the most interesting options for matching urban environmental targets. Electrification is driven by both economics and politics. However, although technology is not yet fully matured and ready for wide commercialisation, a large demonstration project will facilitat ...
Voir le projet
41
Participants partenaires
TERMINÉ
Immunoglobulin IgY pseudomonas A clinical trial for cystic fibrosis treatment (IMPACTT)
Date du début: 1 janv. 2011, Date de fin: 31 déc. 2016,
"Cystic Fibrosis (CF) is a chronically debilitating and life threatening medical condition. Respiratory insufficiency and complications of chronic lung infection lead to long term reduction in quality of life and health and even to premature death. Chronic bacterial infections with Pseudomonas aeruginosa (PA), Staphylococcus aureus and Haemophilus influezae are typical for CF and repeated courses ...
Voir le projet
10
Participants partenaires
TERMINÉ
Quiet Tracks for Sustainable Railway Infrastructures (QUIET-TRACK)
Date du début: 1 juin 2013, Date de fin: 31 mai 2016,
The objective is to provide step changing track based noise mitigation systems and maintenance schemes, to provide reliable improved TSI based rolling noise calculation procedures with harmonized monitoring of the required input parameters and to provide track noise management tools, for use in noise mapping and hot spot action plans according to the END, for use as engineering tools and solutions ...
Voir le projet
12
Participants partenaires
TERMINÉ
Phase II clinical trial of PDGF-BB for the neurological regeneration and recovery in Parkinson´s disease (NRT)
Date du début: 1 janv. 2012, Date de fin: 31 déc. 2015,
"The goal of this project is to perform a European phase II clinical trial to demonstrate that PDGF-BB acts as a unique regenerative therapy for Parkinson’s Disease (PD), aimed at reversing the course of the disease, by promotion of endogenous brain repair mechanisms. Current pharmacological therapies for PD carry side-effects and become less effective as the disease progresses. This causes immen ...
Voir le projet
10
Participants partenaires
TERMINÉ
Augmenting PBGD expression in the liver as a Novel Gene therapy for Acute Intermittent Porphyria (AIPGENE)
Date du début: 1 janv. 2011, Date de fin: 31 oct. 2014,
Acute intermittent porphyria (AIP) is a rare genetic disease in which mutations in the porphobilinogen deaminase (PBGD) gene produce insufficient activity of a protein necessary for heme synthesis. This leads to an accumulation of toxic intermediates resulting in a wide variety of problems including acute, severe abdominal pains, psychiatric and neurological disorders, and muscular weakness. Acute ...
Voir le projet
8
Participants partenaires
TERMINÉ
Viscogel - A chitosan based adjuvant for prophylactic and therapeutic vaccination (ViVac)
Date du début: 1 sept. 2010, Date de fin: 31 déc. 2012,
The overall aim of the ViVac project is to develop and to show safety and efficacy for a new innovative carbohydrate (chitosan) based adjuvant -Viscogel –to be used both in prophylactic and therapeutic vaccination. Three SME participants will contribute with their specific technologies: the unique Viscogel technology, a specific type of cationic peptides with cell-penetrating capacity (LTX) and a ...
Voir le projet
10
Participants partenaires
TERMINÉ
"Health systems and long-term care for older people in Europe – Modelling the INTERfaces and LINKS between prevention, rehabilitation, quality of services and informal care" (INTERLINKS)
Date du début: 1 nov. 2008, Date de fin: 31 déc. 2011,
"The objective of this 3-year project is to construct and validate a general model to describe and analyse long-term care (LTC) systems for older people from a European perspective. The particular aspects of the different emerging national models that currently address long-term care needs in Europe will be used to show how the links to health care services, the quality of LTC services, the incent ...
Voir le projet
16
Participants partenaires
TERMINÉ
The European Advanced Translational Research Infrastructure in Medicine (EATRIS)
Date du début: 1 janv. 2008, Date de fin: 31 déc. 2010,
Efficient translation of research discoveries into industrial application is an essential element to maintain Europe’s competitiveness in the biomedical and health industry. The main bottleneck is the lack and the fragmented nature of essential research infrastructure and know-how, leading to unacceptable delays and/or preventing the development of new innovative medicines. The aim of EATRIS is to ...
Voir le projet